A new analysis from the peripheral arterial disease (PAD) subgroup of the large-scale COMPASS trial show that development of a major adverse limb event — the primary endpoint of the study — is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback